SynthesisPLoS medicine2012
Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies.
Synthesis in PLoS medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 9 syntheses or guidelines pooled it, 214 citations in OpenAlex.
- Pooled it
- Metabolic syndrome and risk of ovarian cancer: a systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Obesity in children and adolescents and the risk of ovarian cancer: A systematic review and dose‒response meta-analysis.PloS one · 2022Pooled it
- Sedentary behaviour in relation to ovarian cancer risk: a systematic review and meta-analysis.European journal of epidemiology · 2021Pooled it
- Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study.British journal of cancer · 2018Pooled it
- Adiposity and ischemic and hemorrhagic stroke: Prospective study in women and meta-analysis.Neurology · 2016Pooled it
- Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium.British journal of cancer · 2015Pooled it
- Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies.Lancet (London, England) · 2015Pooled it
- Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies.The Lancet. Oncology · 2012Pooled it
- Effect of exercise on body composition among women with ovarian cancer.Journal of cancer survivorship : research and practice · 2023Trial
- A Ketogenic Diet Reduces Central Obesity and Serum Insulin in Women with Ovarian or Endometrial Cancer.The Journal of nutrition · 2018Trial
- Cell Cycle Regulator p27 Mediates Body Mass Index Effects in Ovarian Cancer in FIGO-stages I-II.Cancer genomics & proteomicsTrial
- Exposures to Drinking Water Contaminants in Community Water Systems and Risk of Ovarian Cancer in the California Teachers Study Cohort.Environmental health perspectives · 2026Article
- Adiposity and cancer: epidemiology, mechanisms and future perspectives.Nature metabolism · 2026Review
- Modifiable Lifestyle and Environmental Determinants of Ovarian Cancer Risk: Implications for Primary Prevention.Healthcare (Basel, Switzerland) · 2026Review
- Global burden and projected trends of ovarian cancer in older women: A GBD 2021 analysis.Tropical medicine and health · 2026Article
- Global, regional, and national burden of ovarian cancer and uterine cancer attributable to high BMI, 1990-2021: analysis of data from the global burden of disease study 2021.Frontiers in oncology · 2026Article
- Trends and projections of global gynaecological cancer burden: age-period-cohort insights from Global Burden of Disease 2021.BMC women's health · 2025Article
- Disparities, trends, and projections of cancer mortality burden related to high body mass index in China from 2005 to 2030.Cell reports. Medicine · 2025Article
- Cellular origins of mucinous ovarian carcinoma.The Journal of pathology · 2025Review
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
backgroundOnly about half the studies that have collected information on the relevance of women's height and body mass index to their risk of developing ovarian cancer have published their results, and findings are inconsistent. Here, we bring together the worldwide evidence, published and unpublished, and describe these relationships. METHODS AND
findingsIndividual data on 25,157 women with ovarian cancer and 81,311 women without ovarian cancer from 47 epidemiological studies were collected, checked, and analysed centrally. Adjusted relative risks of ovarian cancer were calculated, by height and by body mass index. Ovarian cancer risk increased significantly with height and with body mass index, except in studies using hospital controls. For other study designs, the relative risk of ovarian cancer per 5 cm increase in height was 1.07 (95% confidence interval [CI], 1.05-1.09; p<0.001); this relationship did not vary significantly by women's age, year of birth, education, age at menarche, parity, menopausal status, smoking, alcohol consumption, having had a hysterectomy, having first degree relatives with ovarian or breast cancer, use of oral contraceptives, or use of menopausal hormone therapy. For body mass index, there was significant heterogeneity (p<0.001) in the findings between ever-users and never-users of menopausal hormone therapy, but not by the 11 other factors listed above. The relative risk for ovarian cancer per 5 kg/m(2) increase in body mass index was 1.10 (95% CI, 1.07-1.13; p<0.001) in never-users and 0.95 (95% CI, 0.92-0.99; p=0.02) in ever-users of hormone therapy.
conclusionsOvarian cancer is associated with height and, among never-users of hormone therapy, with body mass index. In high-income countries, both height and body mass index have been increasing in birth cohorts now developing the disease. If all other relevant factors had remained constant, then these increases in height and weight would be associated with a 3% increase in ovarian cancer incidence per decade. Please see later in the article for the Editors' Summary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.